FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089756863> ?p ?o ?g. }

• W3089756863 endingPage "700" @default.
• W3089756863 startingPage "692" @default.
• W3089756863 abstract "Inflammatory markers have prognostic value in various tumors due to the role of inflammatory phenomena at different stages of tumor development. The aim of this study is to demonstrate the prognostic value of these markers, as well as other clinical and analytical variables in patients with metastatic castration-resistant prostate cancer (mCRPC). Prospective cohort study carried out on 80 patients diagnosed with mCRPC. Clinical and analytical data were collected, and the following inflammatory markers were estimated: Absolute Neutrophil Count (ANC), Neutrophil-Lymphocyte Ratio (NLR), Total Platelet Count (TPC), Platelet-Lymphocyte Ratio (PLR), Lymphocyte-Monocyte Ratio (LMR) and Systemic Inflammation Index (SII). The values of albumin, hemoglobin (Hb), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were also determined. Patients with ANC>7500, NLR>3, PLR>150, LMR>3 and/or SII>535,000, presented significantly lower median survival time than the remaining patients, and TPC was the only marker which did not show a significant association. Moreover, NLR, PLR and SII were inversely correlated with survival time. Patients with hypoalbuminemia, anemia, and elevated LDH values had significantly lower median survival time. Albumin and hemoglobin were directly correlated to overall survival time. The need for analgesia was also associated with shorter survival. The values of certain inflammatory markers are associated with shorter survival time in patients with mCRPC, and their use in clinical practice can be considered to evaluate the prognosis and estimate survival. Los marcadores inflamatorios tienen valor pronóstico en diferentes tumores por la intervención de los fenómenos inflamatorios de las diferentes etapas del desarrollo tumoral. El objetivo de este estudio es demostrar el valor pronóstico de estos marcadores, así como de otras variables clínicas y analíticas en pacientes con cáncer de próstata metastásico resistente a la castración (CPRCm). Estudio de cohortes prospectivo realizado en 80 pacientes diagnosticados de CPRCm. Se recogieron datos clínicos y analíticos, estimándose los siguientes marcadores inflamatorios: recuento total de neutrófilos (RTN), ratio neutrófilo/linfocito (RN/L), recuento total de plaquetas (RTP), ratio plaquetas/linfocito (RP/L), ratio linfocito/monocito (RL/M) e índice sistémico de inflamación (ISI). igualmente se determinaron los valores de albúmina, hemoglobina (Hb), fosfatasa alcalina (FA) y lactato deshidrogenasa (LDH). Los pacientes con RTN>7500, RN/L>3, RP/L>150, RL/M>3 y/o ISI>535.000, presentaron una mediana de supervivencia significativamente menores que el resto de pacientes, siendo el RTP el único marcador que no mostró asociación significativa. Además, la RN/L, RP/L y el ISI se correlacionaron inversamente con el tiempo de supervivencia. Los pacientes con hipoalbuminemia, anemia y valores elevados de LDH presentaron medianas de supervivencia significativamente menores. La albumina y la hemoglobina presentaron a su vez una correlación directa con el tiempo total de supervivencia. La necesidad de analgesia también se asoció con una menor supervivencia. Los valores de determinados marcadores inflamatorios se asocian con menor supervivencia en pacientes con CPRCm, pudiendo considerarse su uso en la práctica clínica para evaluar el pronóstico y estimar la supervivencia." @default.
• W3089756863 created "2020-10-08" @default.
• W3089756863 creator A5027806246 @default.
• W3089756863 creator A5031842149 @default.
• W3089756863 creator A5038985952 @default.
• W3089756863 creator A5041941175 @default.
• W3089756863 creator A5043846972 @default.
• W3089756863 creator A5065122372 @default.
• W3089756863 creator A5081866777 @default.
• W3089756863 creator A5085706937 @default.
• W3089756863 date "2020-12-01" @default.
• W3089756863 modified "2023-10-01" @default.
• W3089756863 title "Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer" @default.
• W3089756863 cites W1558239909 @default.
• W3089756863 cites W1982906652 @default.
• W3089756863 cites W1988082986 @default.
• W3089756863 cites W2095914632 @default.
• W3089756863 cites W2128934497 @default.
• W3089756863 cites W2150743941 @default.
• W3089756863 cites W2229919363 @default.
• W3089756863 cites W2315517212 @default.
• W3089756863 cites W2344370229 @default.
• W3089756863 cites W2530956228 @default.
• W3089756863 cites W2535115173 @default.
• W3089756863 cites W2568967701 @default.
• W3089756863 cites W2588316317 @default.
• W3089756863 cites W2589234404 @default.
• W3089756863 cites W2589816513 @default.
• W3089756863 cites W2621170905 @default.
• W3089756863 cites W2716314037 @default.
• W3089756863 cites W2736090010 @default.
• W3089756863 cites W2737075527 @default.
• W3089756863 cites W2756548298 @default.
• W3089756863 cites W2757612972 @default.
• W3089756863 cites W2808760111 @default.
• W3089756863 cites W2815816038 @default.
• W3089756863 cites W2891725196 @default.
• W3089756863 cites W2909318515 @default.
• W3089756863 cites W2944254179 @default.
• W3089756863 cites W4205145397 @default.
• W3089756863 doi "https://doi.org/10.1016/j.acuroe.2020.11.009" @default.
• W3089756863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33010988" @default.
• W3089756863 hasPublicationYear "2020" @default.
• W3089756863 type Work @default.
• W3089756863 sameAs 3089756863 @default.
• W3089756863 citedByCount "5" @default.
• W3089756863 countsByYear W30897568632021 @default.
• W3089756863 countsByYear W30897568632022 @default.
• W3089756863 countsByYear W30897568632023 @default.
• W3089756863 crossrefType "journal-article" @default.
• W3089756863 hasAuthorship W3089756863A5027806246 @default.
• W3089756863 hasAuthorship W3089756863A5031842149 @default.
• W3089756863 hasAuthorship W3089756863A5038985952 @default.
• W3089756863 hasAuthorship W3089756863A5041941175 @default.
• W3089756863 hasAuthorship W3089756863A5043846972 @default.
• W3089756863 hasAuthorship W3089756863A5065122372 @default.
• W3089756863 hasAuthorship W3089756863A5081866777 @default.
• W3089756863 hasAuthorship W3089756863A5085706937 @default.
• W3089756863 hasConcept C121608353 @default.
• W3089756863 hasConcept C126322002 @default.
• W3089756863 hasConcept C143998085 @default.
• W3089756863 hasConcept C181199279 @default.
• W3089756863 hasConcept C2777318727 @default.
• W3089756863 hasConcept C2777761686 @default.
• W3089756863 hasConcept C2778963024 @default.
• W3089756863 hasConcept C2779788118 @default.
• W3089756863 hasConcept C2780192828 @default.
• W3089756863 hasConcept C55493867 @default.
• W3089756863 hasConcept C71924100 @default.
• W3089756863 hasConcept C86803240 @default.
• W3089756863 hasConcept C89560881 @default.
• W3089756863 hasConcept C90924648 @default.
• W3089756863 hasConceptScore W3089756863C121608353 @default.
• W3089756863 hasConceptScore W3089756863C126322002 @default.
• W3089756863 hasConceptScore W3089756863C143998085 @default.
• W3089756863 hasConceptScore W3089756863C181199279 @default.
• W3089756863 hasConceptScore W3089756863C2777318727 @default.
• W3089756863 hasConceptScore W3089756863C2777761686 @default.
• W3089756863 hasConceptScore W3089756863C2778963024 @default.
• W3089756863 hasConceptScore W3089756863C2779788118 @default.
• W3089756863 hasConceptScore W3089756863C2780192828 @default.
• W3089756863 hasConceptScore W3089756863C55493867 @default.
• W3089756863 hasConceptScore W3089756863C71924100 @default.
• W3089756863 hasConceptScore W3089756863C86803240 @default.
• W3089756863 hasConceptScore W3089756863C89560881 @default.
• W3089756863 hasConceptScore W3089756863C90924648 @default.
• W3089756863 hasIssue "10" @default.
• W3089756863 hasLocation W30897568631 @default.
• W3089756863 hasOpenAccess W3089756863 @default.
• W3089756863 hasPrimaryLocation W30897568631 @default.
• W3089756863 hasRelatedWork W2063991010 @default.
• W3089756863 hasRelatedWork W2276485219 @default.
• W3089756863 hasRelatedWork W2556924759 @default.
• W3089756863 hasRelatedWork W2791996962 @default.
• W3089756863 hasRelatedWork W2905398573 @default.
• W3089756863 hasRelatedWork W3013314747 @default.
• W3089756863 hasRelatedWork W3091267404 @default.
• W3089756863 hasRelatedWork W4230563601 @default.

• next